Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q86019387 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010859.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q86019387 | ||
| 024 | ‡a 0000-0003-0028-9820 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q86019387 | ||
| 100 | 0 | ‡a Verónica Corrales-Sánchez ‡c researcher ‡9 en | |
| 400 | 0 | ‡a Verónica Corrales-Sánchez ‡c onderzoeker ‡9 nl | |
| 670 | ‡a Author's Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis | ||
| 670 | ‡a Author's Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer | ||
| 670 | ‡a Author's Circulating DNA and Survival in Solid Tumors | ||
| 670 | ‡a Author's DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer | ||
| 670 | ‡a Author's In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. | ||
| 670 | ‡a Author's In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. | ||
| 670 | ‡a Author's Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses | ||
| 670 | ‡a Author's Mapping Bromodomains in breast cancer and association with clinical outcome | ||
| 670 | ‡a Author's Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. | ||
| 670 | ‡a Author's Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer | ||
| 670 | ‡a Author's Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. | ||
| 670 | ‡a Author's Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer. | ||
| 670 | ‡a Author's Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors | ||
| 670 | ‡a Author's Transcriptome evolution from breast epithelial cells to basal-like tumors. | ||
| 670 | ‡a Author's Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer | ||
| 670 | ‡a Author's Ubiquitin-conjugating enzyme E2T | ||
| 670 | ‡a Author's Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. | ||
| 909 | ‡a (orcid) 0000000300289820 ‡9 1 | ||
| 919 | ‡a pharmacologicalscreeningandtranscriptomicfunctionalanalysesidentifyasynergisticinteractionbetweendasatinibandolaparibintriplenegativebreastcancer ‡A Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer ‡9 1 | ||
| 919 | ‡a phosphokinaseprofileofcolorectaltumorsguidesintheselectionofmultikinaseinhibitors ‡A Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. ‡9 1 | ||
| 919 | ‡a ubiquitinconjugatingenzymee2tube2tanddenticlelessproteinhomologdtlarelinkedtopooroutcomeinbreastandlungcancers ‡A Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. ‡9 1 | ||
| 919 | ‡a ubiquitinconjugatingenzymee2t ‡A Ubiquitin-conjugating enzyme E2T ‡9 1 | ||
| 919 | ‡a transcriptomicanalysesidentifyassociationbetweenmitotickinasespdzbindingkinaseandbub1andclinicaloutcomeinbreastcancer ‡A Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer ‡9 1 | ||
| 919 | ‡a activationofthepi3kmtoraktpathwayandsurvivalinsolidtumorssystematicreviewandmetaanalysis ‡A Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis ‡9 1 | ||
| 919 | ‡a antitumoractivityofthenovelmultikinaseinhibitorec70124intriplenegativebreastcancer ‡A Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer ‡9 1 | ||
| 919 | ‡a circulatingdnaandsurvivalinsolidtumors ‡A Circulating DNA and Survival in Solid Tumors ‡9 1 | ||
| 919 | ‡a dnadamagerelatedgenesandclinicaloutcomeinhormonereceptorpositivebreastcancer ‡A DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer ‡9 1 | ||
| 919 | ‡a insilicoanalysesidentifygenesetsassociatedwithclinicaloutcomeinovariancancerroleofmitotickinases ‡A In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. ‡9 1 | ||
| 919 | ‡a insilicoanalysisguidesselectionofbetinhibitorsfortriplenegativebreastcancertreatment ‡A In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. ‡9 1 | ||
| 919 | ‡a influenceofcompaniondiagnosticsonefficacyandsafetyoftargetedanticancerdrugssystematicreviewandmetaanalyses ‡A Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses ‡9 1 | ||
| 919 | ‡a transcriptomeevolutionfrombreastepithelialcellstobasalliketumors ‡A Transcriptome evolution from breast epithelial cells to basal-like tumors. ‡9 1 | ||
| 919 | ‡a mappingbromodomainsinbreastcancerandassociationwithclinicaloutcome ‡A Mapping Bromodomains in breast cancer and association with clinical outcome ‡9 1 | ||
| 919 | ‡a targetingbasallikebreasttumorswithbromodomainandextraterminaldomainbetandpololikekinaseinhibitors ‡A Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors ‡9 1 | ||
| 919 | ‡a mitoticreadoutgenesconferpooroutcomeinluminalabreastcancertumors ‡A Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. ‡9 1 | ||
| 919 | ‡a syntheticlethalityinteractionbetweenaurorakinasesandchek1inhibitorsinovariancancer ‡A Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer. ‡9 1 | ||
| 996 | ‡2 BNC|981058616798706706 | ||
| 996 | ‡2 BNE|XX5066258 | ||
| 996 | ‡2 NTA|244015724 | ||
| 996 | ‡2 LC|no2013119247 | ||
| 996 | ‡2 BNE|XX5612165 | ||
| 996 | ‡2 BIBSYS|11042709 | ||
| 996 | ‡2 BNF|16973398 | ||
| 996 | ‡2 LC|no2021027797 | ||
| 996 | ‡2 CAOONL|ncf12140437 | ||
| 996 | ‡2 DNB|115520087X | ||
| 996 | ‡2 SUDOC|140835679 | ||
| 996 | ‡2 NUKAT|n 2007142788 | ||
| 996 | ‡2 NTA|426162838 | ||
| 996 | ‡2 PTBNP|1513491 | ||
| 996 | ‡2 ISNI|0000000117712184 | ||
| 996 | ‡2 BNE|XX5429580 | ||
| 996 | ‡2 DNB|137920601 | ||
| 996 | ‡2 RERO|A026071941 | ||
| 996 | ‡2 BNE|XX1499106 | ||
| 996 | ‡2 ISNI|0000000033447424 | ||
| 996 | ‡2 BNE|XX6504593 | ||
| 996 | ‡2 LC|ns2017001721 | ||
| 996 | ‡2 CAOONL|ncf11285999 | ||
| 996 | ‡2 BNC|981058522328006706 | ||
| 996 | ‡2 BIBSYS|9043059 | ||
| 996 | ‡2 LC|n 2019002664 | ||
| 996 | ‡2 LC|n 92058333 | ||
| 996 | ‡2 BNE|XX1039837 | ||
| 996 | ‡2 LC|no2014100681 | ||
| 996 | ‡2 RERO|A021550069 | ||
| 996 | ‡2 BLBNB|000545191 | ||
| 996 | ‡2 BNF|14428232 | ||
| 996 | ‡2 SUDOC|085814091 | ||
| 996 | ‡2 BNCHL|10000000000000000285725 | ||
| 996 | ‡2 ISNI|0000000403406057 | ||
| 996 | ‡2 PLWABN|9812692507205606 | ||
| 996 | ‡2 LC|ns2017002524 | ||
| 996 | ‡2 LC|no2010055141 | ||
| 996 | ‡2 LC|no2013043625 | ||
| 996 | ‡2 ISNI|0000000450146403 | ||
| 996 | ‡2 LC|no2017007902 | ||
| 996 | ‡2 SUDOC|187410216 | ||
| 996 | ‡2 PLWABN|9810681040605606 | ||
| 996 | ‡2 NTA|344363228 | ||
| 996 | ‡2 SUDOC|19542431X | ||
| 996 | ‡2 J9U|987007401518605171 | ||
| 996 | ‡2 LC|n 91049150 | ||
| 996 | ‡2 ISNI|0000000044608561 | ||
| 996 | ‡2 LC|no2004053098 | ||
| 996 | ‡2 ISNI|0000000078019327 | ||
| 996 | ‡2 DNB|106227962X | ||
| 996 | ‡2 BNE|XX6275146 | ||
| 996 | ‡2 LC|no2015144136 | ||
| 996 | ‡2 NII|DA14196090 | ||
| 996 | ‡2 LC|n 2003129740 | ||
| 996 | ‡2 DNB|1287311989 | ||
| 996 | ‡2 BNE|XX4974053 | ||
| 996 | ‡2 PLWABN|9810802457805606 | ||
| 996 | ‡2 BNF|16501738 | ||
| 996 | ‡2 BNC|981058617544106706 | ||
| 996 | ‡2 DBC|87097969963994 | ||
| 996 | ‡2 NUKAT|n 2002039354 | ||
| 996 | ‡2 LC|n 2018043124 | ||
| 996 | ‡2 ISNI|0000000436273078 | ||
| 996 | ‡2 LC|no2017110769 | ||
| 996 | ‡2 BNE|XX5490077 | ||
| 996 | ‡2 ISNI|0000000495782614 | ||
| 996 | ‡2 BNCHL|10000000000000000067440 | ||
| 996 | ‡2 J9U|987007350713805171 | ||
| 996 | ‡2 LC|no2002106287 | ||
| 996 | ‡2 BNE|XX5758429 | ||
| 996 | ‡2 ISNI|0000000093797434 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
